NO20072803L - Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer - Google Patents

Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer

Info

Publication number
NO20072803L
NO20072803L NO20072803A NO20072803A NO20072803L NO 20072803 L NO20072803 L NO 20072803L NO 20072803 A NO20072803 A NO 20072803A NO 20072803 A NO20072803 A NO 20072803A NO 20072803 L NO20072803 L NO 20072803L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
vegf
receptor kinase
growth factor
vascular endothelial
Prior art date
Application number
NO20072803A
Other languages
English (en)
Norwegian (no)
Inventor
Karl-Heinz Thierauch
Martin Krueger
Martin Haberey
Holger Hess-Stumpp
Stuart Ince
Andreas Huth
Rolf Bohlmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20072803L publication Critical patent/NO20072803L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
NO20072803A 2004-11-03 2007-06-01 Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer NO20072803L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090420A EP1655297A1 (en) 2004-11-03 2004-11-03 Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
PCT/EP2005/011709 WO2006048249A1 (en) 2004-11-03 2005-10-28 Nicotinamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20072803L true NO20072803L (no) 2007-08-02

Family

ID=34928841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072803A NO20072803L (no) 2004-11-03 2007-06-01 Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer

Country Status (14)

Country Link
EP (2) EP1655297A1 (ja)
JP (1) JP5069119B2 (ja)
KR (1) KR20070085609A (ja)
CN (1) CN101056870A (ja)
AU (1) AU2005300734A1 (ja)
BR (1) BRPI0515725A (ja)
CA (1) CA2586265C (ja)
ES (1) ES2394324T3 (ja)
IL (1) IL182335A0 (ja)
MX (1) MX2007005340A (ja)
NO (1) NO20072803L (ja)
RU (1) RU2007120691A (ja)
WO (1) WO2006048249A1 (ja)
ZA (1) ZA200705003B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
WO2010022725A1 (en) * 2008-08-27 2010-03-04 Leo Pharma A/S Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
US9546165B2 (en) * 2009-10-06 2017-01-17 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as PDK1 inhibitors
BR112016010566A2 (pt) 2013-11-11 2018-05-02 Syngenta Ltd derivados de 1-(piridazin-3-il)-imidazolidin-2-ona como herbicidas.
SG11201605408RA (en) * 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
DK3094329T3 (en) 2014-01-13 2018-11-19 Aurigene Discovery Tech Ltd BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAC4 INHIBITORS
MX2019011158A (es) 2017-03-31 2019-10-17 Aurigene Discovery Tech Ltd Compuestos y composiciones para tratar trastornos hematologicos.
FI3704108T3 (fi) 2017-10-31 2024-05-23 Curis Inc Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon
CN109942544B (zh) * 2017-12-21 2021-06-11 中国科学院合肥物质科学研究院 一类新型吲唑类衍生物激酶抑制剂
CN108467360B (zh) * 2018-06-22 2021-04-30 江苏美迪克化学品有限公司 一种阿帕替尼的制备方法及其中间体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
PT1387838E (pt) * 2001-05-08 2006-08-31 Schering Ag Derivados de cianoantranilamida e sua utilizacao como farmaco
PL364478A1 (en) * 2001-05-08 2004-12-13 Schering Aktiengesellschaft Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
MXPA04012948A (es) * 2002-07-31 2005-09-12 Schering Ag Inhibidores antranilamidopiridinas vegfr-2 y vegfr-3.
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors

Also Published As

Publication number Publication date
KR20070085609A (ko) 2007-08-27
IL182335A0 (en) 2007-07-24
RU2007120691A (ru) 2008-12-10
CA2586265A1 (en) 2006-05-11
EP1807416B1 (en) 2012-08-29
ES2394324T3 (es) 2013-01-30
EP1655297A1 (en) 2006-05-10
BRPI0515725A (pt) 2008-08-05
AU2005300734A1 (en) 2006-05-11
WO2006048249A1 (en) 2006-05-11
EP1807416A1 (en) 2007-07-18
MX2007005340A (es) 2007-08-17
CN101056870A (zh) 2007-10-17
JP2008518893A (ja) 2008-06-05
CA2586265C (en) 2013-08-06
ZA200705003B (en) 2008-09-25
JP5069119B2 (ja) 2012-11-07

Similar Documents

Publication Publication Date Title
NO20072803L (no) Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer
NO20072802L (no) Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer
NO20072804L (no) Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer
WO2007050783A3 (en) Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CL2008003691A1 (es) Compuestos derivados de 4-(fenil o piridin) pirimidina, inhibidores de la elastasa neutrofila humana; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de hipertension arterial pulmonar, epoc, enfisema pulmonar, entre otras.
NO20090267L (no) Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
NO20064519L (no) Karbolinderivater som er anvendbare ved inhibering av angiogenese
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
NO20071504L (no) Pyrimidinderivanter.
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20084257L (no) Diketopiperazin og piperidin derivater som antivirale midler
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NO20082793L (no) Nye tiofenderivater
DK1543011T3 (da) Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
ATE368662T1 (de) Piperidinyl-thiazol-carbonsäure-derivate als angiogenesis inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application